Latest Insider Transactions at Atea Pharmaceuticals, Inc. (AVIR)
This section provides a real-time view of insider transactions for Atea Pharmaceuticals, Inc. (AVIR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Atea Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Atea Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 03
2020
|
John Vavricka Chief Commercial Officer |
BUY
Conversion of derivative security
|
Indirect |
82,508
+50.0%
|
-
|
|
Nov 03
2020
|
Chung K. Chu > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
176,862
+13.06%
|
-
|
|
Nov 03
2020
|
Jean Pierre Sommadossi President, CEO, and Chairman |
BUY
Conversion of derivative security
|
Indirect |
750,000
+11.24%
|
-
|
|
Nov 03
2020
|
Andrea Corcoran |
BUY
Conversion of derivative security
|
Direct |
133,004
+17.36%
|
-
|
|
Nov 03
2020
|
Franklin M Berger |
BUY
Open market or private purchase
|
Direct |
41,666
+4.84%
|
$999,984
$24.0 P/Share
|
|
Nov 03
2020
|
Franklin M Berger |
BUY
Conversion of derivative security
|
Direct |
759,606
+49.39%
|
-
|
|
Nov 03
2020
|
Polly A. Murphy |
BUY
Conversion of derivative security
|
Indirect |
11,295
+50.0%
|
-
|
|
Nov 03
2020
|
Andrew A. F. Hack Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+4.26%
|
$6,000,000
$24.0 P/Share
|
|
Nov 03
2020
|
Andrew A. F. Hack Director |
BUY
Conversion of derivative security
|
Indirect |
5,365,659
+50.0%
|
-
|